The incidence of skeletal complications experienced by patients with metastatic prostate cancer is illustrated by the placebo group of a recent study of zoledronic acid in men with hormone-refractory prostate cancer

1522. 27.Saad F, Gleason D, Murray R, et al.,“Long-term reduction of bone pain with zoledronic acid in patients with advanced prostate cancer metastatic to bone”, [poster], Poster presented at:American Urological Association Annual Meeting;April 26 May 1, 2003; Chicago, Illinois,Abstract 1473. 28.Major P P, Cook R J, Chen B-L and Zheng M,“Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: a survival-adjusted cumulative incidence analysis”, [abstract], Proc.Am. Soc. Clin. Oncol. (2004), 23: p. 739,Abstract 8058. 29.Carroll P R,Altwein J, Brawley O, et al.,“Management of disseminated prostate cancer”, In: Denis L, Bartsch G, Khoury S, et al, (eds), Prostate Cancer: 3rd International Consultation on Prostate Cancer-Paris. Paris: Health Publications; (2003), pp. 251–284. 30.Smith M R, Eastham J, Gleason D M, Shasha D,Tchekmedyian S and Zinner N,“Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer”, J. Urol. (2003), 169: pp. 2,008–2,012. 31.Padalecki S S, Carreon M, Grubbs B, Cui Y and Guise T A, “Androgen deprivation enhances bone loss and prostate cancer metastases to bone: prevention by zoledronic acid”, Oncology (2003), 17 (suppl 3): p. 32.